Статья
sST2- биомаркер для оценки прогноза и мониторирования больных декомпенсированной сердечной недостаточностью
Обзорная статья посвящена значению определения концентраций нового биомаркера sST2 для оценки прогноза и мониторирования эффективности лечения больных декомпенсированной сердечной недостаточностью во время эпизода декомпенсации и при длительном наблюдении после выписки из стационара. В статье детально проанализирована целесообразность определения концентраций sST2 у больного ОДСН во время госпитализации, при поступлении и выписке из клиники, показано значение изменения уровня биомаркера за период активного лечения для стратификации риска пациентов, представлены оптимальные пороговые значения sST2, на которые следует ориентироваться при выделении больных высокого и очень высокого риска. Подчеркнута важность последующего мониторирования концентрации маркера при длительном наблюдении для предопределения риска развития смерти, повторной декомпенсации/госпитазизации из-за СН, показаны потенциальные преимущества выбора sST2 в качестве наиболее оптимального маркера для серийного измерения при длительном наблюдении, также как и оценки эффективности проводимого лечения больных СН по сравнению с «классическим» вариантом – натрийуретическими пептидами.
1. Writing Group Members, Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD et al. Executive Summary: Heart Disease and Stroke Statistics–2012 Update: A Report from the American Heart Association. Circulation. 2012;125(1):188–97. DOI: 10.1161/CIR.0b013e3182456d46
2. Blecker S, Paul M, Taksler G, Ogedegbe G, Katz S. Heart failure–associated hospitalizations in the United States. Journal of the American College of Cardiology. 2013;61(12):1259–67. DOI: 10.1016/j.jacc.2012.12.038
3. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC et al. Forecasting the Impact of Heart Failure in the United States: A Policy Statement from the American Heart Association. Circulation: Heart Failure. 2013;6(3):606–19. DOI: 10.1161/HHF.0b013e318291329a
4. Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J et al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). European Journal of Heart Failure. 2013;15(7):808–17. DOI: 10.1093/eurjhf/hft050
5. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KKL et al. Long-term trends in the incidence of and survival with heart failure. The New England Journal of Medicine. 2002;347(18):1397–402. DOI: 10.1056/NEJMoa020265
6. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129–200. DOI: 10.1093/eurheartj/ehw128
7. Фомин И. В., Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т., Бадин Ю. М., Галявич А. С. и др. Распространенность хронической сердечной недостаточности в европейской части Российской Федерации. Данные ЭПОХА-ХСН. Журнал Сердечная Недостаточность. 2006;7(1):4-7.
8. Harjola V-P, Follath F, Nieminen MS, Brutsaert D, Dickstein K, Drexler H et al. Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. European Journal of Heart Failure. 2010;12(3):239–48. DOI: 10.1093/eurjhf/hfq002
9. Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Leiro MC, Drozdz J et al. EURObservational Research Programme: The Heart Failure Pilot Survey (ESC-HF Pilot). European Journal of Heart Failure. 2010;12(10):1076–84. DOI: 10.1093/eurjhf/hfq154
10. Krumholz HM, Merrill AR, Schone EM, Schreiner GC, Chen J, Bradley EH et al. Patterns of Hospital Performance in Acute Myocardial Infarction and Heart Failure 30-Day Mortality and Readmission. Circulation: Cardiovascular Quality and Outcomes. 2009;2(5):407–13. DOI: 10.1161/CIRCOUTCOMES.109.883256
11. Скворцов А.А., Протасов В.Н., Нарусов О.Ю., Кошкина Д.Е., Насонова С.Н., Масенко В.П. и др. Определение концентрации растворимого рецептора подавления туморогенности 2-го типа расширяет возможности в стратификации риска больных после перенесенной декомпенсации хронической сердечной недостаточности. Кардиология. 2017;57(1):48-58. DOI: 10.18565/cardio.2017.1.48-58
12. Chow SL, Maisel AS, Anand I, Bozkurt B, de Boer RA, Felker GM et al. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement from the American Heart Association. Circulation. 2017;135(22):e1054–91. DOI: 10.1161/CIR.0000000000000490
13. Luchner A, Behrens G, Stritzke J, Markus M, Stark K, Peters A et al. Long-term pattern of brain natriuretic peptide and N-terminal pro brain natriuretic peptide and its determinants in the general population: contribution of age, gender, and cardiac and extra-cardiac factors. European Journal of Heart Failure. 2013;15(8):859–67. DOI: 10.1093/eurjhf/hft048
14. Januzzi JL. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: The International Collaborative of NT-proBNP Study. European Heart Journal. 2005;27(3):330–7. DOI: 10.1093/eurheartj/ehi631
15. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PWF et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109(5):594–600. DOI: 10.1161/01.CIR.0000112582.16683.EA
16. Wu AHB, Smith A, Wieczorek S, Mather JF, Duncan B, White CM et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. The American Journal of Cardiology. 2003;92(5):628–31. PMID: 12943894
17. Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R et al. Renal Function, Congestive Heart Failure, and Amino-Terminal Pro-Brain Natriuretic Peptide Measurement. Journal of the American College of Cardiology. 2006;47(1):91–7. DOI: 10.1016/j.jacc.2005.08.051
18. Januzzi JL, Mebazaa A, Di Somma S. ST2 and Prognosis in Acutely Decompensated Heart Failure: The International ST2 Consensus Panel. The American Journal of Cardiology. 2015;115(7):26B-31B. DOI: 10.1016/j.amjcard.2015.01.037
19. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137–61. DOI: 10.1161/CIR.0000000000000509
20. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nature Reviews Drug Discovery. 2008;7(10):827–40. DOI: 10.1038/nrd2660
21. Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS letters. 1989;258(2):301–4. PMID: 2532153
22. Klemenz R, Hoffmann S, Werenskiold AK. Serum- and oncoprotein-mediated induction of a gene with sequence similarity to the gene encoding carcinoembryonic antigen. Proceedings of the National Academy of Sciences of the United States of America. 1989;86(15):5708–12. PMID: 2527364
23. Brunner M, Krenn C, Roth G, Moser B, Dworschak M, JensenJarolim E et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Medicine. 2004;30(7):1468–1473. DOI: 10.1007/s00134-004-2184-x
24. Trajkovic V, Sweet MJ, Xu D. T1/ST2—an IL-1 receptorlike modulator of immune responses. Cytokine & Growth Factor Reviews. 2004;15(2–3):87–95. DOI: 10.1016/j.cytogfr.2004.02.004
25. Oshikawa K, Kuroiwa K, Tago K, Iwahana H, Yanagisawa K, Ohno S et al. Elevated Soluble ST2 Protein Levels in Sera of Patients with Asthma with an Acute Exacerbation. American Journal of Respiratory and Critical Care Medicine. 2001;164(2):277–81. DOI: 10.1164/ajrccm.164.2.2008120
26. Kuroiwa K, Arai T, Okazaki H, Minota S, Tominaga S. Identification of Human ST2 Protein in the Sera of Patients with Autoimmune Diseases. Biochemical and Biophysical Research Communications. 2001;284(5):1104–8. DOI: 10.1006/bbrc.2001.5090
27. Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002; 106(23):2961–6. PMID: 12460879
28. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK et al. IL-33, an Interleukin-1-like Cytokine that Signals via the IL-1 Receptor-Related Protein ST2 and Induces T Helper Type 2-Associated Cytokines. Immunity. 2005;23(5):479–90. DOI: 10.1016/j.immuni.2005.09.015
29. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie ANJ, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. Journal of Clinical Investigation. 2007;117(6):1538–49. DOI: 10.1172/JCI30634
30. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. Journal of Immunology (Baltimore, Md.: 1950). 2007;179(4):2551–5. DOI: 10.4049/jimmunol.179.4.2551
31. Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon; J et al. Interleukin-33 Prevents Apoptosis and Improves Survival After Experimental Myocardial Infarction Through ST2 Signaling. Circulation: Heart Failure. 2009;2(6):684–91. DOI: 10.1161/CIRCHEARTFAILURE.109.873240
32. Pérez-Martínez MT, Lacunza-Ruiz J, García de Lara J, NogueraVelasco JA, Lax A, Hernández-Vicente Á et al. Noncardiac Production of Soluble ST2 in ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology. 2018;72(12):1429–30. DOI: 10.1016/j.jacc.2018.06.062
33. Truong QA, Januzzi JL, Szymonifka J, Thai W, Wai B, Lavender Z et al. Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: the BIOCRT study. Heart Rhythm. 2014;11(12):2167–75. DOI: 10.1016/j.hrthm.2014.07.007
34. Bartunek J, Delrue L, Van Durme F, Muller O, Casselman F, De Wiest B et al. Nonmyocardial Production of ST2 Protein in Human Hypertrophy and Failure Is Related to Diastolic Load. Journal of the American College of Cardiology. 2008;52(25):2166–74. DOI: 10.1016/j.jacc.2008.09.027
35. Demyanets S, Kaun C, Pentz R, Krychtiuk KA, Rauscher S, Pfaffenberger S et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. Journal of Molecular and Cellular Cardiology. 2013;60:16–26. DOI: 10.1016/j.yjmcc.2013.03.020
36. Pascual-Figal DA, Pérez-Martínez MT, Asensio-Lopez MC, Sanchez-Más J, García-García ME, Martinez CM et al. Pulmonary Production of Soluble ST2 in Heart Failure. Circulation: Heart Failure. 2018;11(12):e005488. DOI: 10.1161/CIRCHEARTFAILURE.118.005488
37. Dieplinger B, Januzzi JL, Steinmair M, Gabriel C, Poelz W, Haltmayer M et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma — The PresageTM ST2 assay. Clinica Chimica Acta. 2009;409(1–2):33–40. DOI: 10.1016/j.cca.2009.08.010
38. Coglianese EE, Larson MG, Vasan RS, Ho JE, Ghorbani A, McCabe EL et al. Distribution and Clinical Correlates of the Interleukin Receptor Family Member Soluble ST2 in the Framingham Heart Study. Clinical Chemistry. 2012;58(12):1673–81. DOI: 10.1373/clinchem.2012.192153
39. Rehman SU, Mueller T, Januzzi JL. Characteristics of the Novel Interleukin Family Biomarker ST2 in Patients with Acute Heart Failure. Journal of the American College of Cardiology. 2008;52(18):1458–65. DOI: 10.1016/j.jacc.2008.07.042
40. Bayes-Genis A, Zamora E, de Antonio M, Galán A, Vila J, Urrutia A et al. Soluble ST2 Serum Concentration and Renal Function in Heart Failure. Journal of Cardiac Failure. 2013;19(11):768–75. DOI: 10.1016/j.cardfail.2013.09.005
41. Januzzi JL, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL et al. Measurement of the Interleukin Family Member ST2 in Patients with Acute Dyspnea. Journal of the American College of Cardiology. 2007;50(7):607–13. DOI: 10.1016/j.jacc.2007.05.014
42. Henry-Okafor Q , P. Collins S, A. Jenkins C, F. Miller K, J. Maron D, J. Naftilan A et al. Soluble ST2 as a Diagnostic and Prognostic Marker for Acute Heart Failure Syndromes. The Open Biomarkers Journal. 2012;5(1):1–8. DOI: 10.2174/1875318301205010001
43. O’Donoghue ML, Morrow DA, Cannon CP, Jarolim P, Desai NR, Sherwood MW et al. Multimarker Risk Stratification in Patients with Acute Myocardial Infarction. Journal of the American Heart Association. 2016;5(5):e002586. DOI: 10.1161/JAHA.115.002586
44. Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P et al. High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure. Circulation: Heart Failure. 2011;4(2):180–7. DOI: 10.1161/CIRCHEARTFAILURE.110.958223
45. Bayes-Genis A, de Antonio M, Vila J, Peñafiel J, Galán A, Barallat J et al. Head-to-Head Comparison of 2 Myocardial Fibrosis Biomarkers for Long-Term Heart Failure Risk Stratification. Journal of the American College of Cardiology. 2014;63(2):158–66. DOI: 10.1016/j.jacc.2013.07.087
46. Gegenhuber A, Struck J, Dieplinger B, Poelz W, Pacher R, Morgenthaler NG et al. Comparative Evaluation of B-Type Natriuretic Peptide, Mid-Regional Pro-A-type Natriuretic Peptide, Mid-Regional Pro-Adrenomedullin, and Copeptin to Predict 1-year Mortality in Patients with Acute Destabilized Heart Failure. Journal of Cardiac Failure. 2007;13(1):42–9. DOI: 10.1016/j.cardfail.2006.09.004
47. O’Meara E, Prescott MF, Claggett B, Rouleau JL, Chiang L-M, Solomon SD et al. Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circulation: Heart Failure. 2018;11(5): e004446. DOI: 10.1161/CIRCHEARTFAILURE.117.004446
48. Aimo A, Vergaro G, Ripoli A, Bayes-Genis A, Pascual Figal DA, de Boer RA et al. Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure. JACC: Heart Failure. 2017;5(4):287–96. DOI: 10.1016/j.jchf.2016.12.016
49. Emdin M, Aimo A, Vergaro G, Bayes-Genis A, Lupón J, Latini R et al. sST2 Predicts Outcome in Chronic Heart Failure Beyond NT−proBNP and High-Sensitivity Troponin T. Journal of the American College of Cardiology. 2018;72(19):2309–20. DOI: 10.1016/j.jacc.2018.08.2165
50. Lassus J, Gayat E, Mueller C, Peacock WF, Spinar J, Harjola V-P et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study. International Journal of Cardiology. 2013;168(3):2186–94. DOI: 10.1016/j.ijcard.2013.01.228
51. Pascual-Figal DA, Manzano-Fernández S, Boronat M, Casas T, Garrido IP, Bonaque JC et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. European Journal of Heart Failure. 2011;13(7):718–25. DOI: 10.1093/eurjhf/hfr047
52. Socrates T, DeFilippi C, Reichlin T, Twerenbold R, Breidhardt T, Noveanu M et al. Interleukin family member ST2 and mortality in acute dyspnoea: ST2 as a predictor of mortality in dyspnoeic patients. Journal of Internal Medicine. 2010;268(5):493–500. DOI: 10.1111/j.1365-2796.2010.02263.x
53. Pascual-Figal DA, Ordoñez-Llanos J, Tornel PL, Vázquez R, Puig T, Valdés M et al. Soluble ST2 for Predicting Sudden Cardiac Death in Patients with Chronic Heart Failure and Left Ventricular Systolic Dysfunction. Journal of the American College of Cardiology. 2009;54(23):2174–9. DOI: 10.1016/j.jacc.2009.07.041
54. Van Vark LC, Lesman-Leegte I, Baart SJ, Postmus D, Pinto YM, Orsel JG et al. Prognostic Value of Serial ST2 Measurements in Patients with Acute Heart Failure. Journal of the American College of Cardiology. 2017;70(19):2378–88. DOI: 10.1016/j.jacc.2017.09.026
55. Boisot S, Beede J, Isakson S, Chiu A, Clopton P, Januzzi J et al. Serial Sampling of ST2 Predicts 90-Day Mortality Following Destabilized Heart Failure. Journal of Cardiac Failure. 2008;14(9):732–8. DOI: 10.1016/j.cardfail.2008.06.415
56. Breidthardt T, Balmelli C, Twerenbold R, Mosimann T, Espinola J, Haaf P et al. Heart Failure Therapy–Induced Early ST2 Changes May Offer Long-Term Therapy Guidance. Journal of Cardiac Failure. 2013;19(12):821–8. DOI: 10.1016/j.cardfail.2013.11.003
57. Llibre C, Zamora E, Caballero À, Lupón J, Ros A, Benito N et al. The real-life value of ST2 monitoring during heart failure decompensation: impact on long-term readmission and mortality. Biomarkers. 2016;21(3):225–32. DOI: 10.3109/1354750X.2015.1130747
58. Wu AHB, Wians F, Jaffe A. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: Implication on interpretation of test results. American Heart Journal. 2013;165(6):995–9. DOI: 10.1016/j.ahj.2013.02.029
59. Tang WHW, Wu Y, Grodin JL, Hsu AP, Hernandez AF, Butler J et al. Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure. JACC: Heart Failure. 2016;4(1):68–77. DOI: 10.1016/j.jchf.2015.07.015
60. Protasov V N, Skvortsov A A, Narusov O Y, Muksinova M D, Protasova D E, Masenko V P et al. P1595. Significance of sST2 concentration last measurement in serial determination in patients risk stratification after acute heart failure decompensation. European Journal of Heart Failure. 2019;21(Suppl S1):5–592. DOI: 10.1002/ejhf.1488
61. Скворцов А. А., Нарусов О. Ю., Муксинова М. Д., Протасов В. Н., Протасова Д. Е., Кузнецова Т. В. и др. Клиническое значение серийного определения активности современных биомаркеров у больных после декомпенсации сердечной недостаточности: роль sST2 и NT-proBNP при длительном наблюдении. Кардиология. 2018;58(12S):27-41. DOI: 10.18087/cardio.2634
62. Bayes-Genis A, Pascual-Figal D, Januzzi JL, Maisel A, Casas T, Valdés Chávarri M et al. Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure. Revista Espanola De Cardiologia. 2010;63(10):1171–8. PMID: 20875357
63. Gaggin HK, Szymonifka J, Bhardwaj A, Belcher A, De Berardinis B, Motiwala S et al. Head-to-Head Comparison of Serial Soluble ST2, Growth Differentiation Factor-15, and Highly-Sensitive Troponin T Measurements in Patients with Chronic Heart Failure. JACC: Heart Failure. 2014;2(1):65–72. DOI: 10.1016/j.jchf.2013.10.005